-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Jianmei Leavenworth
In cancer, the main obstacle of anti-tumor immunity and immunotherapy is the infiltration of regulatory T cells or T-reg cells into tumors
Researcher Jianmei Leavenworth, MD, Ph.
The UAB research team used melanoma cells implanted under the skin in a mouse model and found that compared with T-reg cells in the spleen, a large number of tumor-infiltrating T-reg cells expressed the transcription factor Blimp1
Leavenworth is an associate professor of neurosurgery at UAB.
This prompted researchers to investigate whether Blimp1 expression in cells regulates tumor immunity
Some of the improved tumor control is due to the loss of inhibitory activity and the conversion of tumor-infiltrating Blimp1-deficient T-reg cells into effector T cells
To support these two findings, UAB researchers found that adoptive transfer of blimp1-deficient TFR cells induced a better anti-tumor response in a mouse model
Most importantly, the loss of Blimp1 converts T-reg and TFR cells into effector T cells, which helps to reprogram the immunosuppressive tumor microenvironment into an immunostimulatory environment, thereby enhancing the immunogenicity of the tumor
"We discovered that a specific immune cell type has a protective relationship with tumors.
Article title
Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade
